Toleranzia has received subscription commitments regarding the exercise of warrants of series TO4 corresponding to approximately 71.14 percent
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Toleranzia AB (the ”Company" or "Toleranzia") has entered into subscription commitments with Flerie Invest AB, Zonda Partners AB, the Company’s CEO and board members regarding warrants of series TO4 with exercise period from 7 October 2024 up to and including 21 October 2024. The subscription commitments amount to a total of approximately SEK 30.9 million, corresponding to approximately 71.14 percent of the issue proceeds that the Company can receive through the warrants of series TO4.
Toleranzia has today received subscription commitments regarding the exercise of warrants of series TO4 from Flerie Invest AB amounting to approximately SEK 30.1 million and Zonda Partners AB amounting to approximately SEK 485,000. In addition to this, the Company’s CEO and board members with holdings of warrants have entered into subscription commitments amounting to approximately SEK 232,000. In total, the subscription commitments correspond to approximately 71.14 percent of the issue proceeds that the Company would receive if all warrants of series TO4 are exercised.
If all warrants of series TO4 are exercised for subscription of shares, the Company will receive approximately SEK 43.4 million before issue related costs.
The exercise period for the warrants of series TO4 runs from 7 October 2024 up to and including 21 October 2024. Full terms and conditions are available on the Company’s website, www.toleranzia.com.
"I am immensely pleased with the confidence in our business shown by Flerie Invest, Zonda Partners and the Company's board members through their subscription commitments. These, together with a good outcome in TO4 in general, are very important and give us the best conditions in the implementation of our upcoming clinical study in patients with myasthenia gravis”, comments Charlotte Fribert, CEO, Toleranzia.
For further information, please contact
Charlotte Fribert - CEO, Toleranzia AB
Tel: +46 763 19 98 98
E-post: charlotte.fribert@toleranzia.com
About Toleranzia AB (publ)
Toleranzia AB (publ) develops medicines that harness the power of the immune system to treat rare autoimmune diseases. The drugs, which target the cause of the disease, can cure or significantly alleviate the disease and not, like current treatments, just reduce symptoms. They have the potential to be the first long-acting or curative treatments that act specifically on the underlying cause of the autoimmune orphan disease for which they are being developed. Toleranzia's shares are listed on Nasdaq First North Growth Market and Mangold Fondkommission AB, 08-503 015 50, CA@mangold.se, is the company's Certified Adviser.